What side effects are problematic for patients prescribed antipsychotic medication? the Maudsley Side Effects (MSE) measure for antipsychotic medication

Psychological Medicine

Volumn 47, Issue 13, 2017, Pages 2369-2378

  Wykes, T ^a,b   Evans, J ^a   Paton, C ^c   Barnes, T R E ^d   Taylor, D ^b,e   Bentall, R ^f   Dalton, B ^a   Ruffell, T ^a   Rose, D ^a   Vitoratou, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Medication side effects; participatory methods; PROM; schizophrenia; self report

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ADVERSE DRUG REACTION; DELPHI STUDY; DEVICES; FEMALE; HUMAN; MALE; MIDDLE AGED; PSYCHOMETRY; QUESTIONNAIRE; REPRODUCIBILITY; SCHIZOPHRENIA; SELF REPORT; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; DELPHI TECHNIQUE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SELF REPORT; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85017600517     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291717000903     Document Type: Article

References (51)

1. Angermeyer MC, Loffler W, Muller P, Schulze B, Priebe S (2011). Patients' relatives' assessment of clozapine treatment. Psychological Medicine 31, 509-517.
2. Ashoorian D, Davidson R, Rock D, Dragovic M, Clifford R (2015). A clinical communication tool for the assessment of psychotropic medication side effects. Psychiatry Research 230, 643-657.
3. Ashoorian D, Davidson R, Rock D, Gudka S, Clifford R (2014). A review of self-report medication side effect questionnaires for mental health patients. Psychiatry Research 219, 664-673.
4. Barnes TR, Paton C, Hancock E, Cavanagh M, Taylor D, Lelliott P (2007). Screening for the metabolic syndrome in people receiving antipsychotic medication in assertive outreach teams: results of the POMH-UK baseline audit. Schizophrenia Bulletin 33, 494-494.
5. Bauml J, Pitschel-Walz G, Volz A, Luscher S, Rentrop M, Kissling W, Jahn T (2016). Psychoeducation improves compliance and outcome in Schizophrenia without an increase of adverse side effects: a 7-year follow-up of the Munich PIP-Study. Schizophrenia Bulletin 42, S62-S70.
6. Bennett J, Done J, Hunt B (1995). Assessing the side-effects of antipsychotic drugs: a survey of CPN practice. Journal of Psychiatric and Mental Health Nursing 2, 177-182.
7. Callard F, Rose D, Wykes T (2012). Close to the bench as well as at the bedside: involving service users in all phases of translational research. Health Expectations 15, 389-400.
8. Cleary A, Walsh F, Connolly H, Hays V, Oluwole B, Macken E, Dowling M (2012). Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service. Journal of Psychiatric and Mental Health Nursing 19, 395-401.
9. Cohen J (1960). A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20, 37-46.
10. Cohen J (1968). Weighted kappa-nominal scale agreement with provision for scaled sisagreement or partial credit. Psychological Bulletin 70, 213-&.
11. Crawford MJ, Robotham D, Thana L, Patterson S, Weaver T, Barber R, Wykes T, Rose D (2011). Selecting outcome measures in mental health: the views of service users. Journal of Mental Health 20, 336-346.
12. Cronbach LJ (1951). Coefficient alpha and the internal structure of tests. Psychometrika 16, 297-334.
13. Day JC, Wood G, Dewey M, Bentall RP (1995). A self-rating scale for measuring neuroleptic side-effects-validation in a Group of Schizophrenic-patients. British Journal of Psychiatry 166, 650-653.
14. Evans J, Rose D, Flach C, Csipke E, Glossop H, Mccrone P, Craig T, Wykes T (2012). VOICE: developing a new measure of service users' perceptions of inpatient care, using a participatorymethodology. Journal ofMental Health 21, 57-71.
15. Faulkner A, Thomas P (2002). User-led research and evidencebased medicine. British Journal of Psychiatry 180, 1-3.
16. Flesch R (1948). A new readability yardstick. Journal of Applied Psychology 32, 221-233.
17. Gamer M, Lemon J, Fellows I, Sing P (2010). irr: Various coefficients of interrater reliability and agreement (Verson 0. 83) [software], Available from (http: \\CRAN. R-project. org/package=irr).
18. Goldberg D (1992). General Health questionnaire (GHQ12). NFER-Nelson: Windsor, UK.
19. Gray R, Wykes T, Parr AM, Hails E, Gournay K (2001). The use of outcome measures to evaluate the efficacy and tolerability of antipsychotic medication: a comparison of Thorn graduate and CPN practice. Journal of Psychiatric and Mental Health Nursing 8, 191-196.
20. Haddad PM, Fleischhacker WW, Peuskens J, Cavallaro R, Lean ME, Morozova M, Reynolds G, Azorin JM, Thomas P, Moller HJ (2014). SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): the development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic Advances in Psychopharmacology 4, 15-21.
21. Hayhurst KP, Drake RJ, Massie JA, Dunn G, Lewis SW (2015). Patients' subjective rating of mental health improvement in a randomised controlled trial. Psychiatry Research 229, 593-595.
22. Hogan TP, Awad AG, Eastwood R (1983). A self-report scale predictive ofdrug compliance in schizophrenics: reliability and discriminative validity. Psychology and Medicine 13, 177-183.
23. Hui CLM, Poon VWY, Ko WT, Miao HY, Chang WC, Lee EHM, Chan SKW, Lin JX, Chen EYH (2016). Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis. Schizophrenia Research 174, 144-149.
24. Jordan S, Hardy B, Coleman M (1999). Medication management: an exploratory study into the role of community mental health nurses. Journal of Advanced Nursing 29, 1068-1081.
25. Landis JR, Koch GG (1977). The measurement of observer agreement for categorical data. Biometrics 33, 159-174.
26. Longden E, Read J (2016). Assessing and reporting the adverse effects of antipsychotic medication: a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clinical Neuropharmacology 39, 29-39.
27. Mccleery A, Ventura J, Kern RS, Subotnik KL, Gretchen-Doorly D, Green MF, Hellemann GS, Nuechterlein KH (2014). Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment. Schizophrenia Research 157, 33-39.
28. Moncrieff J, Azam K, Johnson S, Marston L, Morant N, Darton K, Wood N (2016). Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication. BMC Psychiatry 16, 205.
29. Morrison AP, Hutton P, Shiers D, Turkington D (2012). Antipsychotics: is it time to introduce patient choice? British Journal of Psychiatry 201, 83-84.
30. Morrison P, Meehan T, Stomski NJ (2015). Living with antipsychotic medication side-effects: the experience of Australian mental health consumers. International Journal of Mental Health Nursing 24, 253-261.
31. Morrison P, Stomski NJ, Meehan T (2016). Australian mental health nurses' perspectives about the identification and management of antipsychotic medication side effects: a cross-sectional survey. International Journal of Mental Health Nursing 25, 171-179.
32. Ohlsen RI, Williamson R, Yusufi B, Mullan J, Irving D, Mukherjee S, Page E, Aitchison KJ, Barnes TRE (2008). Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. Journal of Psychopharmacology 22, 323-329.
33. Patel MX, David AS (2007). Medication adherence: predictive factors and enhancement strategies. Psychiatry 6, 357-361.
34. Paton C, Esop R, Young C, Taylor D (2004). Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica 110, 299-305.
35. Pope A, Adams C, Paton C, Weaver T, Barnes TR (2010). Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. British Journal of Psychiatry 197, 67-72.
36. Revelle JB (2010). Combining quality, safety and finance similar toolsets ease transitions between fields. Industrial Engineer 42, 42-46.
37. Rose D, Evans J, Sweeney A, Wykes T (2011). A model for developing outcome measures from the perspectives of mental health service users. International Review of Psychiatry 23, 41-46.
38. Sendt KV, Tracy DK, Bhattacharyya S (2015). A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Research 225, 14-30.
39. Stomski NJ, Morrison P, Meyer A (2016). Antipsychotic medication side effect assessment tools: a systematic review. Australian and New Zealand Journal of Psychiatry 50, 399-409.
40. Taylor D, Young C, Esop R, Paton C, Walwyn R (2004). Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. British Journal of Psychiatry 185, 152-156.
41. Trivedi P, Wykes T (2002). From passive subjects to equal partners-Qualitative review of user involvement in research. British Journal of Psychiatry 181, 468-472.
42. Trujols J, Portella MJ, Iraurgi I, Campins MJ, Sinol N, De Los Cobos JP (2013). Patient-reported outcome measures: are they patient-generated, patient-centred or patientvalued? Journal of Mental Health 22, 555-562.
43. Turner G (1993). Client/CPN contact during the administration of depot medications: implications for practice. In Community Psychiatric Nursing: A Research Perspective (ed. C. Brook and E. White), pp. 71-100.Chapman Hall: London.
44. Van Strien AM, Keijsers CJPW, Derijks HJ, Van MARUM RJ (2015). Rating scales to measure side effects of antipsychotic medication: a systematic review. Journal of Psychopharmacology 29, 857-866.
45. Ventura J, Green MF, Shaner A, Liberman RP (1993). Training and quality assurance with the brief psychiatric rating-scale-the drift busters. International Journal of Methods in Psychiatric Research 3, 221-244.
46. Waddell L, Taylor M (2008). A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. Journal of Psychopharmacology 22, 238-243.
47. Ware J, Kosinski M, Grandek B (2000). SF-36 Health Survey: Manual and Interpretation Guide. Quality Metric Incoporated: Lincoln, RI.
48. Wolters HA, Knegtering H, Van Den Bosch RJ, Wiersma D (2009). Effects and side effects of antipsychotic treatment in schizophrenia: Pros and cons of available self-rating scales. Schizophrenia Research 112, 114-118.
49. Wolters HA, Knegtering R, Wiersma D, Van Den Bosch RJ (2006). Evaluation of the subjects' response to antipsychotics questionnaire. International Clinical Psychopharmacology 21, 63-69.
50. Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, Barnes TR (2007). Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. International Clinical Psychopharmacology 22, 238-243.
51. Yusufi BZ, Mukherjee S, Aitchison K, Dunn G, Page E, Barnes TR (2005). Inter-rater reliability of the antipsychotic non-neurological side effects scale (ANNSERS). Schizophrenia Bulletin 31, 574-574.